IL1B and diabetes mellitus: This finding is in accordance with studies that have reported a reduction in IL-1β expression from the primary human monocytes of DM patients treated with glibenclamide against Mycobacterium bovis Bacillus Calmette Guérin9 and a reduction of type-I IFN production by human monocyte-derived macrophages against M. tuberculosis in the presence of IL-110.